Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
$0.46
$0.43
$0.19
$1.24
$16.71M1.85661,416 shs351,642 shs
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
$1.76
-2.2%
$1.54
$1.12
$3.26
N/A2.0726,278 shs46,267 shs
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
$1.72
+6.8%
$2.51
$1.57
$5.02
$273.48M0.461.31 million shs5.68 million shs
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
$0.00
$0.07
$4.08
$3.50M2.57848,888 shs9.65 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
0.00%0.00%0.00%0.00%0.00%
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
0.00%+16.88%+16.88%+35.33%-21.74%
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
0.00%-44.00%-41.67%-15.26%-61.20%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,910.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
2.9707 of 5 stars
3.55.00.00.02.61.70.0
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
1.5784 of 5 stars
3.61.00.00.01.51.70.0
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
0.00
N/AN/AN/A
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
3.00
Buy$6.00240.91% Upside
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
3.20
Buy$7.20318.60% Upside
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MREO, COCP, PHAS, and CEMI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$7.00 ➝ $5.00
6/20/2025
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $6.00
5/13/2025
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
$48.34M0.35N/AN/A$0.48 per share0.95
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/AN/AN/AN/A$0.94 per shareN/A
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
$10M27.35N/AN/A$0.39 per share4.41
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
$818K0.00N/AN/A($1.93) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
-$23.29M-$1.20N/AN/A-47.03%-113.57%-38.22%N/A
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
-$17.50M-$1.57N/AN/AN/AN/A-135.12%-102.38%8/13/2025 (Estimated)
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
-$43.25M-$0.07N/AN/AN/AN/A-69.33%-57.27%8/12/2025 (Estimated)
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/A

Latest MREO, COCP, PHAS, and CEMI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
-$0.52-$0.23+$0.29-$0.23N/AN/A
5/13/2025Q1 2025
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/AN/AN/AN/AN/A
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/AN/AN/AN/AN/A
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
N/AN/AN/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/A
1.23
1.04
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/A
4.57
4.57
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
N/A
8.92
8.92
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/A
0.47
0.47

Institutional Ownership

CompanyInstitutional Ownership
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
8.65%
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
6.72%
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
62.83%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
49.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
33736.73 million35.51 millionNot Optionable
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
10N/AN/ANot Optionable
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
40159.00 million150.26 millionOptionable
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
6049.86 million44.92 millionNot Optionable

Recent News About These Companies

MedPharm appoints Bill Humphries as new CEO
Medpharm Appoints Chief Executive Officer
PhaseBio Pharmaceuticals Inc.
PhaseBio Pharmaceuticals, Inc. (PHASQ)
Modified Release Neurology Therapeutics Report 202…
Leading innovators in GLP-1 analogues for the pharmaceutical industry
Alcami Announces CEO Transition
8-K: PhaseBio Pharmaceuticals Inc
BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Chembio Diagnostics stock logo

Chembio Diagnostics NASDAQ:CEMI

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Cocrystal Pharma stock logo

Cocrystal Pharma NASDAQ:COCP

$1.76 -0.04 (-2.22%)
Closing price 04:00 PM Eastern
Extended Trading
$1.75 -0.01 (-0.57%)
As of 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Mereo BioPharma Group stock logo

Mereo BioPharma Group NASDAQ:MREO

$1.72 +0.11 (+6.83%)
Closing price 04:00 PM Eastern
Extended Trading
$1.70 -0.02 (-1.45%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

PhaseBio Pharmaceuticals stock logo

PhaseBio Pharmaceuticals NASDAQ:PHAS

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.